Article
Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.
British journal of haematology - 1 Sept 2026
Chan Wei Yee, Al-Yousuf Hannah, Lam Ho Pui Jeff, Leong Sarah, Zheng Jiexin, Burt Richard, Wilson Andrew J, Xu Ke, Stringaris Kate, Alimam Samah, Raj Kavita, Gupta Rajeev, Kottaridis Panagiotis, Tailor Anish, Burgoyne Rebecca, Mansour Marc R, Khwaja Asim, Sellar Rob, Payne Elspeth M, O'Nions Jenny
Abstract excerpt
In FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty-two per cent of patients treated with intention-to-transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain in long-term remission (median follow-up 43 months).
Read the complete abstract on PubMedTopics
- Humans
- Leukemia, Myeloid, Acute
- Sulfonamides
- Bridged Bicyclo Compounds, Heterocyclic